Statement: Cohort 1 of the primary trial included 250 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the mean PFS for this group was just under 7 and a half months.
Primary_evidence: Outcome Measurement:    Progression-Free Survival (PFS)   Time from date of randomization to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurred first. PFS = (first event date minus randomization date +1) divided by 30.4   Time frame: From date of randomization through Day 1 and every 8 weeks thereafter up to 18 months or death Results 1:    Arm/Group Title: Sunitinib + Paclitaxel   Arm/Group Description: Starting sunitinib doses of 25 mg daily. After Cycle 1, escalation to 37.5 mg daily was permitted in the absence of complicated neutropenia and if all 3 Cycle 1 paclitaxel doses were successfully administered at 90 mg/m^2, at discretion of the investigator. Paclitaxel could have been reduced to 65 mg/m^2 based on tolerability; re-escalation to 80 or 90 mg/m^2 upon recovery was permitted.   Overall Number of Participants Analyzed: 242   Median (95% Confidence Interval)   Unit of Measure: Months  7.4        (6.9 to 8.5) Results 2:    Arm/Group Title: Bevacizumab + Paclitaxel   Arm/Group Description: Bevacizumab 10 mg/kg; infusion duration according to standard of care. Paclitaxel starting dose of 90 mg/m^2, as a 1 hour infusion. Paclitaxel could have been reduced to 65 mg/m^2 based on tolerability; re-escalation to 80 or 90 mg/m^2 upon recovery was permitted.   Overall Number of Participants Analyzed: 243   Median (95% Confidence Interval)   Unit of Measure: Months  9.2        (7.7 to 13.0)